ABI-1179 & ABI-5366

About Assembly Biosciences

Assembly Biosciences is a public, clinical-stage biotech based in South San Francisco, advancing a pipeline of novel small-molecule antivirals. Its most advanced programs target recurrent genital herpes, with two clinical candidates showing positive Phase 1b data, and it has secured a significant partnership with Gilead Sciences for these assets. The company also has clinical programs for chronic hepatitis B and D, and a research-stage microbiome program, positioning it in large, underserved viral disease markets. With a valuation of approximately $430 million, the company is focused on progressing its clinical candidates through key milestones.

Therapeutic Areas